Provectus Biopharma (NYSE:PVCT) saw a significant decrease in short interest during the month of September. As of September 30th, there was short interest totalling 1,821,793 shares, a decrease of 26.7% from the September 15th total of 2,487,008 shares. Currently, 0.9% of the company’s stock are sold short. Based on an average trading volume of 4,033,468 shares, the short-interest ratio is presently 0.5 days.

Shares of Provectus Biopharma (NYSE:PVCT) opened at 0.037 on Friday. The stock’s market cap is $7.87 million. Provectus Biopharma has a 52-week low of $0.02 and a 52-week high of $0.55. The company’s 50-day moving average is $0.10 and its 200-day moving average is $0.29.

About Provectus Biopharma

Provectus Biopharmaceuticals, Inc is a development-stage biopharmaceutical company. The Company is engaged in developing pharmaceuticals for oncology and dermatology indications. The Company is focused on developing its prescription drug candidates, PV-10 and PH-10. It is developing PV-10 for treatment of several life threatening cancers, including metastatic melanoma, liver cancer and breast cancer.

5 Day Chart for NYSE:PVCT

Receive News & Stock Ratings for Provectus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Provectus Biopharma and related stocks with our FREE daily email newsletter.